bestbion dx to market sphingotecs predic...sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotecs innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring … more ➔
Galenica exercises over-allotment optionFollowing its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m. more ➔
Spain establishes world-class disease mode...Spanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBLs 6th site in Europe will … more ➔
Roches alectinib superior to crizotinibAfter having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy. more ➔
Nanobiotix completes €25m private placem...French cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation … more ➔
Adaptimmune raises US$42mAs cancer immune therapy specialist Adaptimmunes R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds. more ➔
Menarini expands into CTC liquid biopsyMenarini-Silicon Biosystems Inc., a wholly owned subsidiary of Bologna-based Menarini Group, has completed the take-over of the Cellsearch Circulating Tumour Cell System from Janssen Diagnostic … more ➔
Astellas to acquire Ogeda SAJapanese pharma major Astellas has announced it will take over private Belgian drug developer Ogeda S.A. for €800m. more ➔
Janssen terminates daratumab development i... Genmab A/S has announced that its CD38-targeting Phase II candidate daratumab did not reach the expected ORR in non-Hodgkins lymphoma patients. Co-developer Janssen has decided to terminate development … more ➔
Biostep Forum: Bioeconomy strategy update...The evaluation of the European bioeconomy strategy will take longer than initially planned. According to information given at the Biostep Forum in Brussels, results won’t be available before next … more ➔
